menu
    • menu

    Company profile for EpiBiologics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extrace...
    EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EpiBiologicsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1900 Alameda de las Pulgas Suite 250 San Mateo, CA 94403
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.epibiologics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J, Google Venture Arms Line Up To Back Epibiologics' Series B
    J&J, Google Venture Arms Line Up To Back Epibiologics' Series B

    08 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/jj-gv-line-back-protein-degradation-biotech-epibiologics-107m-series-b

    FIERCE BIOTECH
    08 Jan 2026
    Share Share
    EpiBiologics Presents First Data on c-Met Bispecific Antibody
    EpiBiologics Presents First Data on c-Met Bispecific Antibody

    28 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250428191743/en/EpiBiologics-Presents-First-Data-on-c-Met-Degrading-Bispecific-Antibody

    BUSINESSWIRE
    28 Apr 2025
    Share Share
    EpiBiologics to Present Data on Protein Degradation Platform
    EpiBiologics to Present Data on Protein Degradation Platform

    04 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241104749948/en

    BUSINESSWIRE
    04 Nov 2024
    Share Share
    EpiBiologics Protein Degrader Demonstrate Robust Preclinical Anti-tumor Activity
    EpiBiologics Protein Degrader Demonstrate Robust Preclinical Anti-tumor Activity

    08 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240408193004/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    EpiBiologics Appoints Ann Lee-Karlon as CEO and President
    EpiBiologics Appoints Ann Lee-Karlon as CEO and President

    20 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230720999307/en

    BUSINESSWIRE
    20 Jul 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search